PURPOSE: The organic anion transporter OATP1B3, encoded by SLCO1B3, is involved in the transport of steroid hormones. However, its role in testosterone uptake and clinical outcome of prostatic cancer is unknown. This study examined (a) the SLCO1B3 genotype in cancer cells as well as the uptake of testosterone by cells transfected with genetic variants of SLCO1B3; (b) the expression of OATP1B3 in normal prostate, benign prostatic hyperplasia, and prostatic cancer; and (c) the role of SLCO1B3 haplotype on clinical outcome of Caucasian patients with androgen-independent prostatic cancer. EXPERIMENTAL DESIGN: SLCO1B3 genotype was assessed in the NCI-60 panel of tumor cells by sequencing, whereas testosterone transport was analyzed in Cos-7 cells transfected with WT, 334G, and 699A SLCO1B3 variants. OATP1B3 expression in prostatic tissues was examined by fluorescence microscopy, and the relationship between SLCO1B3 haplotypes and survival was examined in patients. RESULTS: Cells transfected with wild-type (334T/699G) SLCO1B3, or with a vector containing either the 334G or 699A variants, actively transported testosterone, whereas its uptake was impaired in cells transfected with a gene carrying both 334G and 699A single nucleotide polymorphisms. Prostatic cancer overexpresses OATP1B3 compared with normal or benign hyperplastic tissue; patients with SLCO1B3 334GG/699AA haplotype showed longer median survival (8.5 versus 6.4 years; P = 0.020) and improved survival probability at 10 years (42% versus 23%; P < 0.023) than patients carrying TT/AA and TG/GA haplotypes. CONCLUSIONS: The common SLCO1B3 GG/AA haplotype is associated with impaired testosterone transport and improved survival in patients with prostatic cancer.
PURPOSE: The organic anion transporter OATP1B3, encoded by SLCO1B3, is involved in the transport of steroid hormones. However, its role in testosterone uptake and clinical outcome of prostatic cancer is unknown. This study examined (a) the SLCO1B3 genotype in cancer cells as well as the uptake of testosterone by cells transfected with genetic variants of SLCO1B3; (b) the expression of OATP1B3 in normal prostate, benign prostatic hyperplasia, and prostatic cancer; and (c) the role of SLCO1B3 haplotype on clinical outcome of Caucasian patients with androgen-independent prostatic cancer. EXPERIMENTAL DESIGN:SLCO1B3 genotype was assessed in the NCI-60 panel of tumor cells by sequencing, whereas testosterone transport was analyzed in Cos-7 cells transfected with WT, 334G, and 699A SLCO1B3 variants. OATP1B3 expression in prostatic tissues was examined by fluorescence microscopy, and the relationship between SLCO1B3 haplotypes and survival was examined in patients. RESULTS: Cells transfected with wild-type (334T/699G) SLCO1B3, or with a vector containing either the 334G or 699A variants, actively transported testosterone, whereas its uptake was impaired in cells transfected with a gene carrying both 334G and 699A single nucleotide polymorphisms. Prostatic cancer overexpresses OATP1B3 compared with normal or benign hyperplastic tissue; patients with SLCO1B3 334GG/699AA haplotype showed longer median survival (8.5 versus 6.4 years; P = 0.020) and improved survival probability at 10 years (42% versus 23%; P < 0.023) than patients carrying TT/AA and TG/GA haplotypes. CONCLUSIONS: The common SLCO1B3 GG/AA haplotype is associated with impaired testosterone transport and improved survival in patients with prostatic cancer.
Authors: W D Figg; W Dahut; P Duray; M Hamilton; A Tompkins; S M Steinberg; E Jones; A Premkumar; W M Linehan; M K Floeter; C C Chen; S Dixon; D R Kohler; E A Krüger; E Gubish; J M Pluda; E Reed Journal: Clin Cancer Res Date: 2001-07 Impact factor: 12.531
Authors: C A Haiman; M J Stampfer; E Giovannucci; J Ma; N E Decalo; P W Kantoff; D J Hunter Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-07 Impact factor: 4.254
Authors: William D Figg; Yinong Liu; Philip Arlen; James Gulley; Seth M Steinberg; David J Liewehr; Michael C Cox; Suoping Zhai; Serge Cremers; Allyson Parr; Xiaowei Yang; Clara C Chen; Elizabeth Jones; William L Dahut Journal: J Urol Date: 2005-03 Impact factor: 7.450
Authors: Yunhai Cui; Jörg König; Anne T Nies; Marion Pfannschmidt; Michaela Hergt; Werner W Franke; Wibke Alt; Roland Moll; Dietrich Keppler Journal: Lab Invest Date: 2003-04 Impact factor: 5.662
Authors: William L Dahut; James L Gulley; Philip M Arlen; Yinong Liu; Katherine M Fedenko; Seth M Steinberg; John J Wright; Howard Parnes; Clara C Chen; Elizabeth Jones; Catherine E Parker; W Marston Linehan; William D Figg Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim Journal: Pharmacogenet Genomics Date: 2011-03 Impact factor: 2.089
Authors: Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg Journal: Discov Med Date: 2012-01 Impact factor: 2.970
Authors: Arja Kaipainen; Ailin Zhang; Rui M Gil da Costa; Jared Lucas; Brett Marck; Alvin M Matsumoto; Colm Morrissey; Lawrence D True; Elahe A Mostaghel; Peter S Nelson Journal: Prostate Date: 2019-08-02 Impact factor: 4.104
Authors: Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg Journal: Mol Biotechnol Date: 2010-02 Impact factor: 2.695
Authors: Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen Journal: Pharmacogenet Genomics Date: 2010-02 Impact factor: 2.089